Adenovirus p53 purging for human breast cancer stem cell products

Manabu Hirai, Linda S. Kelsey, Daniel C. Maneval, Mei Vaillancourt, James E Talmadge

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Tumor cell (TC) contamination of stem cell products can contribute to relapse after high dose chemotherapy and stem cell rescue. A new purging technology using replication-deficient recombinant adenovirus (Adv) containing the p53 tumor suppressor gene (Adv-p53) has been suggested to reduce tumor contamination of autologous stem cell product. We demonstrate herein a safe and effective Adv-p53 purging procedure using four human breast cancer TC lines. Multiple parameters need to be achieved to successfully purge stem cell products, including a high cell:virus ratio, a small incubation volume, a long incubation time and 37°C rather than room temperature. These parameters are all interrelated and equally important for the inhibition of TC clonogenic growth. In our studies, we also observed that Adv could nonspecifically inhibit TC clonogenic growth, although Adv-p53 treatment led to a significantly greater inhibition of clonogenic growth by cells expressing mutated p53. The presence of peripheral stem cell (PSC) products was found to decrease the effect of Adv-p53 on TC clonogenic growth, suggesting that PSC products could compete with TC for infection by recombinant Adv. However, X-Gal staining after incubation with Adv containing-galactosidase demonstrated that PSC products were 2000-fold more resistant to Adv infection than TC. We conclude that a 4-hour incubation of stem cell products (2 x 108/ml) with 4 x 1011 Adv-p53 particles is sufficient to completely purge TC with no effect on hematopoietic cell function.

Original languageEnglish (US)
Pages (from-to)97-105
Number of pages9
JournalActa Haematologica
Volume101
Issue number2
DOIs
StatePublished - Jan 1 1999

Fingerprint

Neoplastic Stem Cells
Adenoviridae
Breast Neoplasms
Stem Cells
Neoplasms
Adenoviridae Infections
Growth
Galactosidases
Tumor Cell Line
Tumor Suppressor Genes
Staining and Labeling
Viruses
Technology
Recurrence
Drug Therapy
Temperature

Keywords

  • Adenovirus
  • Breast cancer
  • Clonogenic growth
  • Purging
  • p53

ASJC Scopus subject areas

  • Hematology

Cite this

Adenovirus p53 purging for human breast cancer stem cell products. / Hirai, Manabu; Kelsey, Linda S.; Maneval, Daniel C.; Vaillancourt, Mei; Talmadge, James E.

In: Acta Haematologica, Vol. 101, No. 2, 01.01.1999, p. 97-105.

Research output: Contribution to journalArticle

Hirai, M, Kelsey, LS, Maneval, DC, Vaillancourt, M & Talmadge, JE 1999, 'Adenovirus p53 purging for human breast cancer stem cell products', Acta Haematologica, vol. 101, no. 2, pp. 97-105. https://doi.org/10.1159/000040931
Hirai, Manabu ; Kelsey, Linda S. ; Maneval, Daniel C. ; Vaillancourt, Mei ; Talmadge, James E. / Adenovirus p53 purging for human breast cancer stem cell products. In: Acta Haematologica. 1999 ; Vol. 101, No. 2. pp. 97-105.
@article{dd639079894840e4b3aa5fd6c323c07e,
title = "Adenovirus p53 purging for human breast cancer stem cell products",
abstract = "Tumor cell (TC) contamination of stem cell products can contribute to relapse after high dose chemotherapy and stem cell rescue. A new purging technology using replication-deficient recombinant adenovirus (Adv) containing the p53 tumor suppressor gene (Adv-p53) has been suggested to reduce tumor contamination of autologous stem cell product. We demonstrate herein a safe and effective Adv-p53 purging procedure using four human breast cancer TC lines. Multiple parameters need to be achieved to successfully purge stem cell products, including a high cell:virus ratio, a small incubation volume, a long incubation time and 37°C rather than room temperature. These parameters are all interrelated and equally important for the inhibition of TC clonogenic growth. In our studies, we also observed that Adv could nonspecifically inhibit TC clonogenic growth, although Adv-p53 treatment led to a significantly greater inhibition of clonogenic growth by cells expressing mutated p53. The presence of peripheral stem cell (PSC) products was found to decrease the effect of Adv-p53 on TC clonogenic growth, suggesting that PSC products could compete with TC for infection by recombinant Adv. However, X-Gal staining after incubation with Adv containing-galactosidase demonstrated that PSC products were 2000-fold more resistant to Adv infection than TC. We conclude that a 4-hour incubation of stem cell products (2 x 108/ml) with 4 x 1011 Adv-p53 particles is sufficient to completely purge TC with no effect on hematopoietic cell function.",
keywords = "Adenovirus, Breast cancer, Clonogenic growth, Purging, p53",
author = "Manabu Hirai and Kelsey, {Linda S.} and Maneval, {Daniel C.} and Mei Vaillancourt and Talmadge, {James E}",
year = "1999",
month = "1",
day = "1",
doi = "10.1159/000040931",
language = "English (US)",
volume = "101",
pages = "97--105",
journal = "Acta Haematologica",
issn = "0001-5792",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Adenovirus p53 purging for human breast cancer stem cell products

AU - Hirai, Manabu

AU - Kelsey, Linda S.

AU - Maneval, Daniel C.

AU - Vaillancourt, Mei

AU - Talmadge, James E

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Tumor cell (TC) contamination of stem cell products can contribute to relapse after high dose chemotherapy and stem cell rescue. A new purging technology using replication-deficient recombinant adenovirus (Adv) containing the p53 tumor suppressor gene (Adv-p53) has been suggested to reduce tumor contamination of autologous stem cell product. We demonstrate herein a safe and effective Adv-p53 purging procedure using four human breast cancer TC lines. Multiple parameters need to be achieved to successfully purge stem cell products, including a high cell:virus ratio, a small incubation volume, a long incubation time and 37°C rather than room temperature. These parameters are all interrelated and equally important for the inhibition of TC clonogenic growth. In our studies, we also observed that Adv could nonspecifically inhibit TC clonogenic growth, although Adv-p53 treatment led to a significantly greater inhibition of clonogenic growth by cells expressing mutated p53. The presence of peripheral stem cell (PSC) products was found to decrease the effect of Adv-p53 on TC clonogenic growth, suggesting that PSC products could compete with TC for infection by recombinant Adv. However, X-Gal staining after incubation with Adv containing-galactosidase demonstrated that PSC products were 2000-fold more resistant to Adv infection than TC. We conclude that a 4-hour incubation of stem cell products (2 x 108/ml) with 4 x 1011 Adv-p53 particles is sufficient to completely purge TC with no effect on hematopoietic cell function.

AB - Tumor cell (TC) contamination of stem cell products can contribute to relapse after high dose chemotherapy and stem cell rescue. A new purging technology using replication-deficient recombinant adenovirus (Adv) containing the p53 tumor suppressor gene (Adv-p53) has been suggested to reduce tumor contamination of autologous stem cell product. We demonstrate herein a safe and effective Adv-p53 purging procedure using four human breast cancer TC lines. Multiple parameters need to be achieved to successfully purge stem cell products, including a high cell:virus ratio, a small incubation volume, a long incubation time and 37°C rather than room temperature. These parameters are all interrelated and equally important for the inhibition of TC clonogenic growth. In our studies, we also observed that Adv could nonspecifically inhibit TC clonogenic growth, although Adv-p53 treatment led to a significantly greater inhibition of clonogenic growth by cells expressing mutated p53. The presence of peripheral stem cell (PSC) products was found to decrease the effect of Adv-p53 on TC clonogenic growth, suggesting that PSC products could compete with TC for infection by recombinant Adv. However, X-Gal staining after incubation with Adv containing-galactosidase demonstrated that PSC products were 2000-fold more resistant to Adv infection than TC. We conclude that a 4-hour incubation of stem cell products (2 x 108/ml) with 4 x 1011 Adv-p53 particles is sufficient to completely purge TC with no effect on hematopoietic cell function.

KW - Adenovirus

KW - Breast cancer

KW - Clonogenic growth

KW - Purging

KW - p53

UR - http://www.scopus.com/inward/record.url?scp=0032908718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032908718&partnerID=8YFLogxK

U2 - 10.1159/000040931

DO - 10.1159/000040931

M3 - Article

C2 - 10202240

AN - SCOPUS:0032908718

VL - 101

SP - 97

EP - 105

JO - Acta Haematologica

JF - Acta Haematologica

SN - 0001-5792

IS - 2

ER -